Intuitive Surgical, Inc. (NASDAQ:ISRG – Get Free Report) SVP Mark Brosius sold 2,128 shares of the firm’s stock in a transaction on Tuesday, October 22nd. The stock was sold at an average price of $515.00, for a total value of $1,095,920.00. Following the completion of the sale, the senior vice president now directly owns 273 shares of the company’s stock, valued at $140,595. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link.
Mark Brosius also recently made the following trade(s):
- On Thursday, October 24th, Mark Brosius sold 22 shares of Intuitive Surgical stock. The stock was sold at an average price of $510.79, for a total value of $11,237.38.
- On Thursday, September 12th, Mark Brosius sold 2,115 shares of Intuitive Surgical stock. The stock was sold at an average price of $491.91, for a total value of $1,040,389.65.
Intuitive Surgical Stock Down 0.1 %
Shares of Intuitive Surgical stock opened at $511.27 on Friday. Intuitive Surgical, Inc. has a twelve month low of $254.85 and a twelve month high of $523.34. The business has a 50-day moving average price of $487.34 and a 200 day moving average price of $441.45. The firm has a market cap of $182.10 billion, a PE ratio of 82.20, a P/E/G ratio of 5.11 and a beta of 1.39.
Hedge Funds Weigh In On Intuitive Surgical
Wall Street Analysts Forecast Growth
A number of equities analysts recently issued reports on ISRG shares. Redburn Atlantic upgraded Intuitive Surgical from a “neutral” rating to a “buy” rating and raised their target price for the stock from $380.00 to $510.00 in a research note on Friday, August 2nd. Piper Sandler restated an “overweight” rating and issued a $538.00 target price (up previously from $495.00) on shares of Intuitive Surgical in a research note on Friday, October 18th. Royal Bank of Canada raised their target price on Intuitive Surgical from $525.00 to $555.00 and gave the stock an “outperform” rating in a research note on Friday, October 18th. Citigroup raised their target price on Intuitive Surgical from $512.00 to $560.00 and gave the stock a “buy” rating in a research note on Thursday, August 22nd. Finally, Oppenheimer reiterated a “market perform” rating on shares of Intuitive Surgical in a research note on Friday, October 18th. One analyst has rated the stock with a sell rating, five have given a hold rating and fourteen have given a buy rating to the company. Based on data from MarketBeat.com, Intuitive Surgical presently has a consensus rating of “Moderate Buy” and a consensus price target of $513.74.
Check Out Our Latest Report on ISRG
About Intuitive Surgical
Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.
Further Reading
- Five stocks we like better than Intuitive Surgical
- What is a Dividend Harvesting Strategy and How Can Investors Profit from it?
- Texas Roadhouse Stock Steering for New Highs This Year
- Why Invest in 5G? How to Invest in 5G Stocks
- Monopar Therapeutics Skyrockets 400% on Licensing Deal
- ETF Screener: Uses and Step-by-Step Guide
- Tractor Supply Stock Pulls Back: A Prime Buying Opportunity
Receive News & Ratings for Intuitive Surgical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intuitive Surgical and related companies with MarketBeat.com's FREE daily email newsletter.